GeneDx: Melanie Duquette, Jennifer Brendel

Sep 12, 2023

GeneDx has named Melanie Duquette as chief growth officer and promoted Jennifer Brendel to chief of corporate affairs. Duquette comes to GeneDx from Invitae, where she served as head of US sales. Brendel had been chief commercial officer at GeneDx. Both will report directly to CEO and President Katherine Stueland.

Breaking News

FDA Grants Emergency Use Authorizations for Point-of-Care COVID Tests from Tangen Biosciences, SD Biosensor
Top Five Articles on GenomeWeb Last Week: FDA Proposal for LDT Oversight, Adela $48M Financing, More
FDA Grants Marketing Authorization for Invitae Hereditary Cancer DNA Sequencing Test
Compact Gene Editing Enzyme May Improve Success Rates of Gene Therapies
People in the News at Veracyte, Invitae, Mount Sinai, InterVenn Biosciences, Applied BioCode, More

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.